Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Hydrogenation Catalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Discover the advanced enantioselective process for HMG-CoA inhibitors described in CN1636004A. Achieve high purity statin intermediates with reduced waste and scalable catalytic methods.
Patent CN101090770B discloses a dual-ligand Rh-catalyzed system for asymmetric hydrogenation, delivering superior enantioselectivity and cost efficiency for API manufacturing.
Patent CN1968927B details a novel Ru-catalyzed route for high-purity quinoline intermediates used in bronchodilators, offering significant cost reduction in API manufacturing.
Patent CN1842523A details a novel asymmetric hydrogenation process for enantiomerically pure beta-amino alcohols, offering significant cost reduction in API manufacturing.
Patent CN1119332C details a novel asymmetric hydrogenation route for azepine intermediates, offering cost-effective and scalable production for kinase inhibitors like Balanol.
Patent CN101675020A details a novel asymmetric hydrogenation method for high-purity optically active aldehydes like citronellal, offering enhanced catalyst stability and supply chain reliability.
Patent CN1761642A details an efficient asymmetric hydrogenation process for chiral beta-amino acids, offering significant cost reduction and supply chain reliability for API manufacturing.
Patent CN109942514B details a cost-effective L-phenylalanine route for Atazanavir intermediates, offering high purity and scalable manufacturing solutions.
Patent CN85103245A details novel rhodium-diphosphine complexes enabling high-yield asymmetric hydrogenation for pharmaceutical intermediates with reduced catalyst loading.
Patent CN101039894A reveals stabilized Rh-catalyzed asymmetric hydrogenation for high-purity citronellal production, offering significant cost reduction in flavor manufacturing.
Patent CN101941900A reveals a novel Ru-catalyzed asymmetric hydrogenation route for high-purity chiral acids, offering significant cost reduction in API manufacturing and enhanced supply chain stability.
Novel Ru-BINAP catalyzed route for (R)-5'-methoxylaudanosine. High purity >99.98% ee, non-genotoxic process, scalable for Mivacurium Chloride production.
Patent CN102076634A details enantioselective hydrogenation of N-H imines. Discover cost-effective routes for high-purity pharmaceutical intermediates without protection steps.
Novel Rh-catalyzed asymmetric hydrogenation route for Pramipexole. Higher yield, lower cost, industrial scale ready. Ideal for pharma intermediates.
Patent CN114874134A details a protection-free asymmetric synthesis of nicotine using Ir-catalysis, offering high ee values and scalable manufacturing for pharmaceutical intermediates.
Patent CN1139576C details a novel iridium-catalyzed asymmetric hydrogenation process for producing high-purity dextromethorphan intermediates with enhanced supply chain reliability.
Patent CN114644614B details a novel 3-step synthesis for L-nicotine achieving >99.9% optical purity. Discover cost-effective, scalable manufacturing solutions for pharmaceutical intermediates.
Patent CN114644614B reveals a novel 3-step route to L-nicotine with >99.9% ee. Discover cost-effective manufacturing and supply chain advantages for pharma intermediates.
Patent CN1566084A reveals novel water-soluble diamines enabling green asymmetric hydrogenation. Discover cost-effective API intermediate manufacturing solutions.
Patent CN101346352B reveals efficient Rh-catalyzed asymmetric reduction for Mitiglinide. Offers high optical purity and industrial scalability for diabetes drug intermediates.